<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2025-11-28</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2025-11-28</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>84</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>4</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ“° å…¬ä¼—å·</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
æ–°å‹CAR-Tç»†èƒç–—æ³•æˆåŠŸé€†è½¬å¹¶é¢„é˜²è¡°è€ç›¸å…³è‚ é“é—®é¢˜ï¼›é¦–æ¬¡ç³»ç»Ÿç»˜åˆ¶éäººçµé•¿ç±»å…¨èº«å¤šç»„å­¦è¡°è€å›¾è°±ï¼Œæ­ç¤ºå™¨å®˜è¡°è€å·®å¼‚æœºåˆ¶ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- æ¢ç´¢ä¸‰çº§æ·‹å·´ç»“æ„åœ¨èƒƒç™Œä¸­çš„é¢„ååŠŸèƒ½ã€‚<br />
- é‰´å®šå¹²æ‰°ç´ è¯±å¯¼çš„è¡°è€CD8Tç»†èƒåŠå…¶å¯¹å…ç–«æ²»ç–—çš„å½±å“ã€‚<br />
- æ­ç¤ºä»£è°¢é‡ç¼–ç¨‹åœ¨ç™Œç—‡æ²»ç–—ä¸å…ç–«åˆºæ¿€ä¸­çš„ä½œç”¨ã€‚<br />
- ç ”ç©¶æ°¨åŸºé…¸ä»£è°¢ã€è„‚è´¨ä»£è°¢åœ¨ç–¾ç—…ä¸­çš„å…³é”®ä½œç”¨ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- EASi-seqï¼šå•ç»†èƒå¾®ç”Ÿç‰©åŸºå› ç»„æµ‹åºæŠ€æœ¯ã€‚<br />
- SpaLinkerï¼šæ•´åˆå…¨åŸºå› ç»„å’Œç©ºé—´æµ‹åºæ•°æ®è¯†åˆ«ç©ºé—´è‚¿ç˜¤å¾®ç¯å¢ƒç‰¹å¾ã€‚<br />
- gggenomesåŒ…ï¼šå¤šå±‚æ¬¡åŸºå› ç»„å›¾è°±ç»˜åˆ¶ã€‚<br />
- cNMFï¼šä¼˜åŒ–å•ç»†èƒRNAæµ‹åºæ•°æ®è§£æåŸºå› è¡¨è¾¾ç¨‹åºã€‚</p>
<h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
åˆ©ç”¨æ¶²æ€æ´»æ£€è¡¨è§‚åŸºå› ç»„å­¦æ­ç¤ºAPOE Îµ4ä¸é˜¿å°”èŒ¨æµ·é»˜ç—…ï¼ˆADï¼‰ç›¸å…³ç”²åŸºåŒ–ç‰¹å¾ï¼›å¼€å‘æ–°å‹CHANGE-seq-BEæŠ€æœ¯å®ç°ç¢±åŸºç¼–è¾‘å™¨è¯±å¯¼çš„è„±é¶æ´»æ€§å…¨åŸºå› ç»„é«˜åˆ†è¾¨ç‡æ£€æµ‹ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- è‚¿ç˜¤æœºåˆ¶ç ”ç©¶ï¼šKRASæŠ‘åˆ¶è€è¯æ€§ã€MITFé¶å‘ã€IDH2/SRSF2çªå˜ååŒæ•ˆåº”ã€STAT3é€šè·¯åœ¨è‚ç™Œä¸­çš„ä½œç”¨ã€ SHIP2é€šè·¯åœ¨é£Ÿç®¡é³çŠ¶ç»†èƒç™Œï¼ˆeSCCï¼‰ä¸­çš„è°ƒæ§ã€‚<br />
- ç–¾ç—…è¡¨è§‚é—ä¼ å­¦ï¼šADçš„APOE Îµ4ç›¸å…³ç”²åŸºåŒ–ã€IDH2çªå˜è¯±å¯¼çš„åŸºå› å†…è¡¨è§‚é—ä¼ å¤±è°ƒã€‚<br />
- ç»†èƒè°ƒæ§ä¸å‘è‚²ï¼šç³–å°¿ç—…å¯¹ç‰™å‘¨ç‚å®¿ä¸»ååº”çš„å½±å“ã€äººç±»è†å…³èŠ‚å‘è‚²çš„å¤šç»„å­¦åˆ†æã€CDCA8ç»´æŒDNAç”²åŸºåŒ–æœºåˆ¶ã€MBD-2åœ¨DNAç”²åŸºåŒ–æ— å…³ç”Ÿç‰©ä½“ä¸­çš„åŠŸèƒ½ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- <strong>æ–°å‹æ£€æµ‹æŠ€æœ¯</strong>ï¼šCHANGE-seq-BEç”¨äºç²¾ç¡®è¯„ä¼°ç¢±åŸºç¼–è¾‘å™¨è„±é¶æ´»æ€§ã€‚<br />
- <strong>å¤šç»„å­¦æ•´åˆ</strong>ï¼šscMultiome-seqå’Œç©ºé—´HDæ•°æ®ç”¨äºåˆ†æå‘è‚²è¿‡ç¨‹ã€‚<br />
- <strong>æ¶²æ€æ´»æ£€</strong>ï¼šåˆ©ç”¨è¡¨è§‚åŸºå› ç»„å­¦è¿›è¡ŒADè¯Šæ–­ä¸åˆ†å‹ã€‚</p>
<h3>ğŸ”¬ æœŸåˆŠæ–‡ç« </h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
é’å°‘å¹´å’Œå¹´è½»æˆäººç™Œç—‡çš„è½¬ç§»å¤å‘æ˜¯å¯¼è‡´æ—©æœŸæ­»äº¡çš„å…³é”®é©±åŠ¨å› ç´ ï¼Œå…¶å‘ç”Ÿç‡å’Œç”Ÿå­˜ç‡æ•°æ®ä»éœ€æ·±å…¥ç ”ç©¶ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- è¯„ä¼°æ´›æ‹‰æ›¿å°¼åœ¨æ™šæœŸ ROS1 é˜³æ€§éå°ç»†èƒè‚ºç™Œï¼ˆNSCLCï¼‰ä¸­çš„ç–—æ•ˆä¸å®‰å…¨æ€§ã€‚<br />
- ä¼°ç®—é’å°‘å¹´å’Œå¹´è½»æˆäººæ—©æœŸç™Œç—‡æ‚£è€…è½¬ç§»å¤å‘çš„ç´¯è®¡å‘ç”Ÿç‡ï¼ˆCMIï¼‰ï¼Œå¹¶åˆ†æè¯Šæ–­æ—¶ä¸è½¬ç§»æ€§ç–¾ç—…çš„ç”Ÿå­˜ç‡å·®å¼‚ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- å›é¡¾æ€§é˜Ÿåˆ—ç ”ç©¶æ–¹æ³•ç”¨äºåˆ†æç™Œç—‡è½¬ç§»å¤å‘æ•°æ®ã€‚<br />
- è¯„ä¼°æ–°å‹ç¬¬ä¸‰ä»£é…ªæ°¨é…¸æ¿€é…¶æŠ‘åˆ¶å‰‚ï¼ˆTKIï¼‰æ´›æ‹‰æ›¿å°¼åœ¨é¶å‘ ROS1 çªå˜ NSCLC ä¸­çš„æ½œåŠ›ã€‚</p>
<h3>ğŸ§ª åšå®¢æ›´æ–°</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
æ–°å‹çŸ¥è¯†å¢å¼ºåŸºç¡€æ¨¡å‹scKGBERTç”¨äºå•ç»†èƒè½¬å½•ç»„åˆ†æï¼ŒåŠRNAæµ‹åºæ­ç¤ºOTULINè°ƒæ§tauè¡¨è¾¾ï¼Œä¸ºé˜¿å°”èŒ¨æµ·é»˜ç—…æ²»ç–—å¸¦æ¥æ–°æœºé‡ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- åˆ©ç”¨RNAæµ‹åºæŠ€æœ¯æ·±å…¥è§£æè„‘è›‹ç™½OTULINåœ¨tauè›‹ç™½ç”Ÿæˆä¸­çš„å…³é”®è°ƒæ§ä½œç”¨ã€‚<br />
- å¼€å‘çŸ¥è¯†å¢å¼ºå‹åŸºç¡€æ¨¡å‹scKGBERTï¼Œæ•´åˆå¤§è§„æ¨¡RNAæµ‹åºæ•°æ®ä¸è›‹ç™½è´¨äº’ä½œç½‘ç»œï¼Œæå‡å•ç»†èƒè½¬å½•ç»„åˆ†æçš„ç²¾åº¦ã€‚<br />
- æ¨åŠ¨å¤§è§„æ¨¡RNAæµ‹åºæŠ€æœ¯åœ¨åŠŸèƒ½åŸºå› ç»„å­¦å’ŒRNAç–—æ³•å‘ç°ä¸­çš„åº”ç”¨ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- é¦–æ¬¡å°†å¤§è§„æ¨¡RNAæµ‹åºæ•°æ®ä¸è›‹ç™½è´¨äº’ä½œç½‘ç»œç›¸ç»“åˆï¼Œæ„å»ºçŸ¥è¯†å¢å¼ºå‹åŸºç¡€æ¨¡å‹ï¼ˆscKGBERTï¼‰ã€‚<br />
- åº”ç”¨é«˜ä¿çœŸRNAæµ‹åºæŠ€æœ¯ç”Ÿæˆå¤§è§„æ¨¡åŠŸèƒ½åŸºå› ç»„å­¦æ•°æ®ï¼ŒåŠ é€ŸAIé©±åŠ¨çš„é¶ç‚¹å‘ç°ã€‚</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ“° å…¬ä¼—å· (34æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>æ–‡çŒ®åˆ†äº«--å•ç»†èƒä¸ç©ºé—´è½¬å½•ç»„å­¦æ­ç¤ºä¸‰çº§æ·‹å·´ç»“æ„åœ¨èƒƒç™Œä¸­çš„é¢„ååŠŸèƒ½</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šå•ç»†èƒç©ºé—´äº¤å“ä¹<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šæ·‹å·´ã€å•ç»†èƒã€ç©ºé—´è½¬å½•ç»„ã€ç©ºé—´ç»„å­¦ã€è½¬å½•ç»„<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šæ–‡çŒ®åˆ†äº«--å•ç»†èƒä¸ç©ºé—´è½¬å½•ç»„å­¦æ­ç¤ºä¸‰çº§æ·‹å·´ç»“æ„åœ¨èƒƒç™Œä¸­çš„é¢„ååŠŸèƒ½<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg2MDY1NTYyOQ==&amp;mid=2247499165&amp;idx=1&amp;sn=ec2e6b632a9c1033ae3ec292998384de" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>æ–‡çŒ®åˆ†äº«ï½œAdvanced Scienceï½œEASi-seqï¼šå•ç»†èƒå¾®ç”Ÿç‰©åŸºå› ç»„æµ‹åºæŠ€æœ¯</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç‹æ°¸æˆLab<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå¾®ç”Ÿç‰©ã€æµ‹åºã€å•ç»†èƒã€åŸºå› ç»„<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šå¾®ç”Ÿç‰©ç»„å…·æœ‰ç‰©ç§å¤šæ ·æ€§å’Œé—ä¼ å¼‚è´¨æ€§ï¼Œè¿™ä¸»è¦æºäºæ ¸å¿ƒåŸºå› ç»„çš„å·®å¼‚ä»¥åŠè´¨ç²’å’Œè½¬åº§å­ç­‰ç§»åŠ¨é—ä¼ å…ƒä»¶ã€‚<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzkxMDY1MjU1OA==&amp;mid=2247488592&amp;idx=1&amp;sn=f5bcc4d0dc1bc61d5bac2d327f6515ba" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>ç©ºé—´ç»„å­¦ | CellGenomics | SpaLinkeré€šè¿‡æ•´åˆå…¨åŸºå› ç»„å’Œç©ºé—´æµ‹åºæ•°æ®è¯†åˆ«ä¸è¡¨å‹ç›¸å…³è”çš„ç©ºé—´è‚¿ç˜¤å¾®ç¯å¢ƒç‰¹å¾</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šBioJournal Link<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€æµ‹åºã€ç©ºé—´ç»„å­¦ã€åŸºå› ç»„<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg5NjgxNjkwOA==&amp;mid=2247503147&amp;idx=2&amp;sn=9c2522fffed16bb952ac00c49bc24bd6" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>Nature Agingï¼šæ–°å‹CAR-Tç»†èƒç–—æ³•ï¼Œé€†è½¬å¹¶é¢„é˜²è¡°è€ç›¸å…³è‚ é“é—®é¢˜</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿç‰©ä¸–ç•Œ<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè¡°è€ã€agingã€Tç»†èƒã€è‚ é“<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šé¶å‘uPARçš„CAR-Tç»†èƒç–—æ³•<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&amp;mid=2247790877&amp;idx=2&amp;sn=6f19f89391824e228f39f9b1d295f1b8" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> â­ <strong>8+å¹²æ¹¿ç»“åˆæ¨¡æ¿æ–‡ç« ï¼Œç»“åˆåˆ†å‹å’Œå»ºæ¨¡è¯†åˆ«è„‚è´¨ä»£è°¢å…³é”®åŸºå› ï¼Œè¿›å±•å¢æ®–ï¼Œå‡‹äº¡ï¼Œä»£è°¢å’Œå…ç–«å¾®ç¯å¢ƒçš„å®éªŒéªŒè¯ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€å…ç–«å¾®ç¯å¢ƒã€ä»£è°¢<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247504084&amp;idx=6&amp;sn=5ad010cece058746e8350c957d566100" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> â­ <strong>æœ€æ–°14+å¹²æ¹¿ç»“åˆSCIï¼Œä½œè€…é‰´å®šå‡ºå¹²æ‰°ç´ è¯±å¯¼çš„è¡°è€ CD8T ç»†èƒå¹¶æ­ç¤ºå…¶å¯¹å…ç–«æ²»ç–—çš„å½±å“ã€‚è¡°è€è™½è€ï¼Œä½†æ˜¯çœŸçš„ç«ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€è¡°è€ã€Tç»†èƒ<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247504084&amp;idx=4&amp;sn=5205e900eeb88578539986c7d8b83fc4" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> â­ <strong>10.6åˆ†éè‚¿ç˜¤å¹²æ¹¿ç»“åˆç”Ÿä¿¡ï¼Œé¶å‘ CD177 + ä¸­æ€§ç²’ç»†èƒå‡è½»ç¼ºè¡€å†çŒæ³¨æŸä¼¤ã€‚é€‚åˆåŠ¨ç‰©å»ºæ¨¡æµ‹åºæ€è·¯ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€æµ‹åºã€ç”Ÿä¿¡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247504084&amp;idx=3&amp;sn=09cd8694eb0e1bb64b086484acbc501a" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> â­ <strong>å„ä¸ªå‘è¡¨çš„8åˆ†ç”Ÿä¿¡ï¼ŒåŸºäºé“œæ­»äº¡çš„è‚¿ç˜¤åˆ†å‹ï¼Œç»“åˆWGCNA+æœºå™¨å­¦ä¹ +SCISSORç®—æ³•+å•ç»†èƒ+è¡¨è¾¾éªŒè¯ã€‚å…¶å®ä¸€ç‚¹ä¹Ÿä¸éš¾ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€å•ç»†èƒã€ç”Ÿä¿¡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247504084&amp;idx=1&amp;sn=54cbae11dd0b33b388f9bcf193ef6f15" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> â­ <strong>Immunityï¼šåˆ˜å…‰æ…§ã€ç”°çƒ¨ç­‰å…«ä½ä¸­å¤–ç§‘å­¦å®¶å…±æ¢è¡°è€ä¸å…ç–«å‰æ²¿</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šäººä½“è›‹ç™½è´¨ç»„å¯¼èˆªè®¡åˆ’<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€immunityã€è¡°è€<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&amp;mid=2247507704&amp;idx=1&amp;sn=5cdf65a63addecc474d25ba2d9a7ba5c" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>cNMFéè´ŸçŸ©é˜µåˆ†è§£PBMCå•ç»†èƒæ•°æ®å­¦ä¹ </strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šå•ç»†èƒå¤©åœ°<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šBç»†èƒã€å•ç»†èƒ<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šcNMFæ˜¯å¯¹å•ç»†èƒRNAæµ‹åºæ•°æ®ä¼˜åŒ–çš„è®¡ç®—æ¡†æ¶ï¼Œé€šè¿‡å…±è¯†éè´ŸçŸ©é˜µåˆ†è§£è§£æåŸºå› è¡¨è¾¾ç¨‹åºã€‚å¤šå±‚æ¬¡è¾“å‡ºä½“ç³»ä»æ•°å­¦åˆ†è§£å»¶ä¼¸è‡³ç”Ÿç‰©å­¦è§£é‡Šï¼Œä¼˜åŒ–å¤„ç†é«˜ç»´ç¨€ç–æ•°æ®ï¼Œé‡‡ç”¨å…±è¯†æ¡†æ¶ç¡®ä¿ç¨³å®šæ€§ï¼Œéè´Ÿçº¦æŸå¢å¼ºå¯è§£é‡Šæ€§ï¼Œæ¢ç´¢å¤æ‚ç»†èƒç¾¤ä½“åŠŸèƒ½ã€‚<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzI1Njk4ODE0MQ==&amp;mid=2247534004&amp;idx=1&amp;sn=c7bb978bb287f36b7bcd43fc857f0ee0" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 24 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-å…¬ä¼—å·">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (44æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>GSE310675 èƒ°è…ºç™Œä¸­KRASæŠ‘åˆ¶å‰‚è€è¯æœºåˆ¶çš„é‰´å®š</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€resistanceã€KRAS<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributor : Andrew M WatersSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensKRAS inhibitors (KRASi) targeting various KRAS mutations have entered clinical trials for pancreatic cancer. Despite promising preliminary clinical responses, most patients relapse due to intrinsic and acquired resistance. Thus, combination treatments are essential to extend the efficacy of KRAS-targeted therapies. To further determine genetic mechanisms of KRASi resistance, we performed KRASi-anchored CRISPR-Cas9 loss-of-function screens in KRAS G12D-, KRAS G12R-, and KRAS Q61H-mutant PDAC cell lines, using six KRASi, to identify genes, that when lost, modulate sensitivity to KRAS inhibition. We pharmacologically validated several hits from our screens, including EGFR, CK2 p110 alpha and p110 gamma, and YAP, by combining targeted inhibitors with KRASi. We determined that KRAS Q61H-mutant PDAC cell lines are intrinsically less dependent on KRAS for survival than other KRAS mutational subtypes. Further, we found that EGFR inhibitor erlotinib synergized with the RAS(ON) multi-selective inhibitor RMC-7977 in KRAS Q61H-mutant PDAC cell lines, and in cell lines with highly active EGFR, by mitigating ERK rebound activity. We also developed KRASi-resistant cell lines and observed sustained ERK MAPK dependence in the KRASi-resistant cell lines despite decreased ERK activity. Our findings enhance the understanding of KRASi intrinsic and acquired resistance and identify therapeutic vulnerabilities that can potentially be exploited for KRASi combination therapies in patients with PDAC.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310675" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>GSE311578 æ¨è¿›é˜¿å°”èŒ¨æµ·é»˜ç—…ä¸ªæ€§åŒ–åŒ»ç–—ï¼šæ¶²ä½“æ´»æ£€è¡¨è§‚åŸºå› ç»„å­¦æ­ç¤ºAPOE Îµ4è¿é”ç”²åŸºåŒ–ç‰¹å¾</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šAlzheimerã€methylation<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributor : Maite MendiorozSeries Type : Methylation profiling by genome tiling arrayOrganism : Homo sapiensRecent studies show that patients with Alzheimerâ€™s disease (AD) harbor specific methylation marks in the brain that, if accessible, could be used as epigenetic biomarkers. Liquid biopsy enables the study of circulating cell-free DNA (cfDNA) fragments originated from dead cells, including neurons affected by neurodegenerative processes. Here, we isolated and epigenetically characterized plasma cfDNA from 35 patients with AD and 35 cognitively healthy controls by using the InfiniumÂ® MethylationEPIC BeadChip array. Bioinformatics analysis was performed to identify differential methylation positions (DMPs) and regions (DMRs), including APOE Îµ4 genotype stratified analysis. Plasma pTau181 (Simoa) and cerebrospinal fluid (CSF) core biomarkers (Fujirebio) were also measured and correlated with differential methylation marks. Validation was performed with bisulfite pyrosequencing and bisulfite cloning sequencing. Epigenome-wide cfDNA analysis identified 102 DMPs associated with AD status. Most DMPs correlated with clinical cognitive and functional tests including 60% for Mini-Mental State Examination (MMSE) and 80% for Global Deterioration Scale (GDS), and with AD blood and CSF biomarkers. In silico functional analysis connected 30 DMPs to neurological processes, identifying key regulators such as SPTBN4 and APOE genes. Several DMRs were annotated to genes previously reported to harbor epigenetic brain changes in AD (HKR1, ZNF154, HOXA5, TRIM40, ATG16L2, ADAMST2) and were linked to APOE Îµ4 genotypes. Notably, a DMR in the HKR1 gene, previously shown to be hypermethylated in the AD hippocampus, was validated in cfDNA from an orthogonal perspective. These results support the feasibility of studying cfDNA to identify potential epigenetic biomarkers in AD. Thus, liquid biopsy could improve non-invasive AD diagnosis and aid personalized medicine by detecting epigenetic brain markers in blood.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311578" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>GSE283855 é€šè¿‡åŸºäºç‰‡æ®µçš„å‘ç°ç›´æ¥é¶å‘ç™ŒåŸºå› å°çœ¼ç•¸å½¢ç›¸å…³è½¬å½•å› å­ (MITF) [RNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šregex:onco(logy|logist|gene|genic)ã€RNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Deborah Castelletti ; Fanny Mermet-Meillon ; Aurore Desplat ; Kayhan Gabriel Akyel ; Edward J Oakeley ; Ulrike Naumann ; Louise Barys ; Fei JiSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensDespite the improvement of therapeutic options for melanoma, patients with advanced metastatic disease are still in high need of durable and tolerated treatments. Analysis of clinical data from patients receiving targeted and/or immunotherapy, along with genetic and functional studies in preclinical melanoma models, show that lineage addiction to MITF is retained throughout disease progression, thus providing the rationale to pursue therapeutic inhibition of MITF. However, direct targeting of MITF or other basic helix-loop-helix leucine zipper (bHLH-LZ) transcription factors is unprecedented. Here, we report on the fragment-based discovery of high-affinity ligands for MITF. Fragment screening by NMR led to the discovery of weak binders to the kink pocket of MITF, which were optimized to sub-micromolar affinity by structure-based design enabled by crystallography and biophysics. Furthermore, NMR experiments and molecular dynamics simulations revealed a dynamic conformational exchange of the two helices in the asymmetric homodimer, which is perturbed by ligand binding. This work advances our knowledge on direct targeting of bHLH-LZ domains and sets the basis to further explore pharmacological inhibition of MITF.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE283855" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> <strong>GSE280581 IDH2 çªå˜å¼•èµ·çš„åŸºå› å†…è¡¨è§‚é—ä¼ å¤±è°ƒä¸ SRSF2 çªå˜ååŒä½œç”¨ï¼Œå¯¼è‡´å…³é”®è½¬å½•è°ƒæ§å› å­çš„é”™è¯¯å‰ªæ¥ [RNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šRNA-seqã€epigenetic<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Aristeidis G Telonis ; Maria E FigueroaSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensGenes impacting DNA methylation (DNAme), like IDH2, are frequently co-mutated with splicing factors, like SRSF2, in acute myeloid leukemia (AML). These co-occurring mutations are associated with more aggressive phenotypes but the underlying molecular mechanisms remain elusive. To address this gap, we profiled wild-type, IDH2R140Q or SRSF2P95 single-mutants and IDH2R140Q/SRSF2P95 double-mutant AMLs at a deep resolution level. We find a unique set of mis-spliced genes and differentially methylated CpGs in double-mutants. Mis-spliced exons are enriched in CCNG splicing enhancers and in the corresponding DNAme changes. Using a machine-learning model, we can accurately predict exon inclusion levels from proximal CpGs. These CpGs are more likely to overlap with footprints of RNA-binding and chromatin-modifying complexes but not transcription factors. We also report unique gene expression profiles associated with each genotype; however, the differentially expressed genes do not overlap with mis-spliced transcripts. Instead, the mis-spliced genes encode for proteins that interact with the gene regulatory complexes that control the expression of these differentially expressed genes. Thus, we propose a mechanism where synergism between aberrant DNAme and splicing leads to the mis-splicing of key components in gene regulatory complexes, thus resulting in the aberrant gene expression profiles characteristic of these AMLs.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE280581" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> <strong>GSE277137 å•ç»†èƒRNAæµ‹åºåˆ†æç³–å°¿ç—…å¯¹ç‰™å‘¨ç‚å®¿ä¸»ååº”çš„å½±å“</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsequencingã€single-cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Bushra Alghamdi ; Min Liu ; Mi Zhou ; Michael Troka ; Michael Gonzalez ; Dana GravesSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusDiabetes exert a disruptive immune respose process. We use single-cell RNA-sequencing (scRNA-seq) data from gingiva from normalglycemic and diabetic mice to investigate the impact of diabetes on immune cells and to understand their role in host response.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE277137" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> <strong>GSE260926 äººç±»è†å…³èŠ‚å‘è‚²çš„å•ç»†èƒå¤šç»„æµ‹åºå’Œå•ç»†èƒç©ºé—´é«˜æ¸…æ•°æ®</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsingle-cellã€spatial<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : G Senevirathne ; Andrew Zhu ; Divya Venkatasubramanian ; Terence D Capellini ; April M CraftSeries Type : Expression profiling by high throughput sequencing ; Genome binding/occupancy profiling by high throughput sequencing ; OtherOrganism : Homo sapiensCartilage plays a crucial role in skeletal development and function, and abnormal development contributes to genetic and age-related skeletal disease. Compromises to the integrity of joint-lining articular cartilage in particular lead to debilitating chronic degenerative diseases including osteoarthritis. To better understand how human articular cartilage develops in vivo, we jointly profiled the transcriptome and open chromatin regions in individual nuclei recovered from distal femora at 2 fetal timepoints. We used these multiomic data to predict transcription factor-based regulatory networks that are important for articular chondrocyte differentiation. We developed a human pluripotent stem cell platform for interrogating the function of predicted transcription factors during chondrocyte differentiation and identified new biological roles for CREB5. We expect new regulatory networks we uncovered using multiomic data to be important for promoting cartilage health and treating disease, and our platform to be a useful tool for studying cartilage development in vitro.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE260926" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> <strong>GSE275343 æŒç»­å­˜åœ¨çš„ STAT3 ç›¸å…³æŸ“è‰²è´¨æ„è±¡å†…çš„åè°ƒåŸºå› è¡¨è¾¾ä¿ƒè¿›è‚ç»†èƒç™Œè¿›å±• [CHIP-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcarcinomaã€ChIP-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Sunyoung Jang ; Sumin Yoon ; Kyung H YooSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensp-STAT3 has emerged as a critical modulator of hepatocellular carcinoma (HCC) progression; however, its role in 3D chromatin architecture and the expression of genes linked to HCC aggressiveness remains largely unexplored. Here, we elucidate the function of p-STAT3 in establishing stable regulatory regions known as FIREs, characterized by highly active interactions and the potential to alter topologically associated domains (TADs). Our results demonstrate that expression of genes located within FIREs is highly correlated, and upregulation, these genes play a crucial role in driving phenotypes, including HCC invasion and tube formation. Notably, p-STAT3-associated FIREs maintain chromatin activation despite pharmacological interventions targeting STAT3, suggesting a mechanism that failure to suppress the expression of genes associated with HCC aggressiveness leads to drug resistance. These findings provide novel insights into how the 3D genome structure associated with p-STAT3 promotes HCC progression and drug resistance, highlighting the therapeutic potential of targeting 3D chromatin dynamics in HCC.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE275343" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> <strong>GSE275342 æŒç»­å­˜åœ¨çš„ STAT3 ç›¸å…³æŸ“è‰²è´¨æ„è±¡å†…çš„åè°ƒåŸºå› è¡¨è¾¾ä¿ƒè¿›è‚ç»†èƒç™Œè¿›å±• [RNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcarcinomaã€RNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Sunyoung Jang ; Sumin Yoon ; Kyung H YooSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensp-STAT3 has emerged as a critical modulator of hepatocellular carcinoma (HCC) progression; however, its role in 3D chromatin architecture and the expression of genes linked to HCC aggressiveness remains largely unexplored. Here, we elucidate the function of p-STAT3 in establishing stable regulatory regions known as FIREs, characterized by highly active interactions and the potential to alter topologically associated domains (TADs). Our results demonstrate that expression of genes located within FIREs is highly correlated, and upregulation, these genes play a crucial role in driving phenotypes, including HCC invasion and tube formation. Notably, p-STAT3-associated FIREs maintain chromatin activation despite pharmacological interventions targeting STAT3, suggesting a mechanism that failure to suppress the expression of genes associated with HCC aggressiveness leads to drug resistance. These findings provide novel insights into how the 3D genome structure associated with p-STAT3 promotes HCC progression and drug resistance, highlighting the therapeutic potential of targeting 3D chromatin dynamics in HCC.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE275342" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> <strong>GSE311580 ç©ºé—´å¤šç»„å­¦åˆ†ææ­ç¤ºäº†MRPé©±åŠ¨çš„å„¿ç«¥ARDSå…ç–«å’Œè¡€ç®¡åŠŸèƒ½éšœç¢</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€spatial<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Gabrielle Antonio-Carreon ; Fernando Guimaraes ; Arutha Kulasinghe ; Ahmed MehdiSeries Type : OtherOrganism : Homo sapiensDSP RNA profling using the whole transcriptome atlas kit was performed on a cohort of ARDS and uninfected lung samples from paediatric patients.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311580" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>GSE311547 åˆ©ç”¨ CHANGE-seq-BE å¯¹ç¢±åŸºç¼–è¾‘å™¨è¯±å¯¼çš„è„±é¶æ´»æ€§è¿›è¡Œçµæ•ä¸”æ— åå€šçš„å…¨åŸºå› ç»„åˆ†æ [ABE é¶æ ‡çš„ gRNA æµ‹åº]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsequencingã€genome<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Varun Katta ; Yichao Li ; Shengdar TsaiSeries Type : OtherOrganism : synthetic constructTo identify potential contaminating gRNAs, we adapted a gRNA sequencing assay based on an established SMARTer smRNA sequencing technology. We evaluated five research-grade gRNAs from three synthetic gRNA manufacturer suppliers (A, B and C). We detected the presence of contaminating gRNAs in CBLB and CIITA gRNAs from supplier A (batch 1), with frequency ranging from 0.09% to 2.71%.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311547" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 34 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ”¬ æœŸåˆŠæ–‡ç«  (3æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨3æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>ç™Œç—‡é’å°‘å¹´å’Œå¹´è½»æˆäººè½¬ç§»æ€§å¤å‘</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: é‡è¦æ€§ å°½ç®¡æ²»ç–—å–å¾—äº†è¿›æ­¥ï¼Œè½¬ç§»æ€§å¤å‘ä»æ˜¯å¯¼è‡´å‘ç—…å’Œæ­»äº¡ç‡çš„ä¸»è¦åŸå› ã€‚å…³äºè½¬ç§»æ€§å¤å‘åå‘ç”Ÿç‡å’Œå­˜æ´»ç‡çš„å®è¯æ•°æ®ä»ç„¶æœ‰é™ï¼Œå› ä¸ºç™Œç—‡ç™»è®°æœºæ„å†æ¥ä¸æ”¶é›†å¤å‘æ•°æ®ã€‚ç›®çš„ï¼šä¼°ç®—è¢«è¯Šæ–­ä¸ºæ—©æœŸç–¾ç—…é’å°‘å¹´å’Œé’å¹´çš„è½¬ç§»å¤å‘ç´¯è®¡å‘ç”Ÿç‡ï¼ˆCMIï¼‰ï¼Œå¹¶æ¯”è¾ƒè¯Šæ–­æ—¶ä¸è½¬ç§»æ€§ç–¾ç—…çš„ç”Ÿå­˜ç‡ã€‚è®¾è®¡ã€åœ°ç‚¹ã€å‚ä¸è€… è¿™æ˜¯ä¸€é¡¹å›é¡¾æ€§é˜Ÿåˆ—ç ”ç©¶ï¼Œå¯¹è±¡ä¸º 2006 å¹´è‡³ 2018 å¹´é—´è¯Šæ–­ä¸ºéè½¬ç§»æ€§ç™Œç—‡çš„ 15 è‡³ 39 å²é’å°‘å¹´å’Œé’å¹´ã€‚é’å°‘å¹´å’Œå¹´è½»æˆäººæ˜¯ä»åŠ å·ç™Œç—‡ç™»è®°å¤„è¯†åˆ«çš„ï¼Œè¿™äº›ç™»è®°å¤„ä¸åŠ å·åŒ»ç–—æœåŠ¡éƒ¨çš„ä½é™¢ã€æ€¥è¯Šå’Œé—¨è¯Šæ‰‹æœ¯æ¥è§¦ç›¸å…³è”ã€‚æ•°æ®åˆ†ææ—¶é—´ä¸º 2023 å¹´ 12 æœˆè‡³ 2025 å¹´ 6 æœˆã€‚æš´éœ² ç™Œç—‡ç±»å‹ï¼ŒåŒ…æ‹¬é»‘è‰²ç´ ç˜¤ã€è‚‰ç˜¤ä»¥åŠä¹³è…ºç™Œã€å®«é¢ˆç™Œã€ç»“ç›´è‚ ç™Œã€ç¾ä¸¸ç™Œå’Œç”²çŠ¶è…ºç™Œã€‚ä¸»è¦ç»“å±€å’ŒæŒ‡æ ‡ è½¬ç§»æ€§å¤å‘é€šè¿‡å›½é™…ç–¾ç—…åˆ†ç±»ç¬¬ä¹ç‰ˆåŠç¬¬åç‰ˆä¸´åºŠä¿®è®¢ç‰ˆç¡®å®šï¼Œè½¬ç§»æ€§ç–¾ç—…ä»£ç åœ¨ç™Œç—‡è¯Šæ–­åè‡³å°‘ 6 ä¸ªæœˆæˆ–ç”±æ½œåœ¨ç™Œç—‡æ­»å› ç¡®å®šã€‚éšè®¿æŒç»­è‡³ 2020 å¹´<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1993805936442060800/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>é…ªæ°¨é…¸æ¿€é…¶æŠ‘åˆ¶å‰‚ä¸­çš„æ´›æ‹‰æ›¿å°¼-æœªå‘ç°çš„æ™šæœŸ ROS1 é˜³æ€§éå°ç»†èƒè‚ºç™Œï¼šä¸€é¡¹äºŒæœŸééšæœºä¸´åºŠè¯•éªŒã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šæ¿€é…¶<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: é‡è¦æ€§ ROS1 é‡æ’è¾ƒä¸ºç½•è§ï¼Œä½†åœ¨æ™šæœŸéå°ç»†èƒè‚ºç™Œï¼ˆNSCLCï¼‰ä¸­æ˜¯ä¸€ä¸ªæœ‰å¸å¼•åŠ›çš„æ²»ç–—é¶ç‚¹ã€‚å…‹é‡Œä½æ›¿å°¼ã€æ©æ›²æ›¿å°¼å’Œé›·æ³¢æ›¿å°¼å·²è·ç¾å›½é£Ÿå“è¯å“ç›‘ç£ç®¡ç†å±€æ‰¹å‡†ç”¨äºæ²»ç–— ROS1 é˜³æ€§ NSCLC çš„è¯ç‰©ã€‚æ´›æ‹‰æ›¿å°¼æ˜¯ä¸€ç§è„‘ç©¿é€å‰‚ã€ç¬¬ä¸‰ä»£é…ªæ°¨é…¸æ¿€é…¶æŠ‘åˆ¶å‰‚ï¼ˆTKIï¼‰ï¼Œé¶å‘ ROS1 å’Œ ALK;ç„¶è€Œï¼Œå…¶å¯¹æ™šæœŸ ROS1 é˜³æ€§æ‚£è€…çš„ç–—æ•ˆå’Œå®‰å…¨æ€§å°šä¸æ¸…æ¥šã€‚ç›®çš„ï¼šè¯„ä¼°æ´›æ‹‰æ›¿å°¼å¯¹æ™šæœŸ ROS1 é˜³æ€§éå°ç»†èƒè‚ºç™Œæ‚£è€…ä»æœªæ¥å—ä»»ä½• TKI æ²»ç–—çš„ç–—æ•ˆå’Œå®‰å…¨æ€§ã€‚è®¾è®¡ã€ç¯å¢ƒä¸å‚ä¸è€… è¯¥å¤šä¸­å¿ƒç¬¬äºŒæœŸééšæœºä¸´åºŠè¯•éªŒæ‹›å‹Ÿäº†æ™šæœŸ ROS1 é˜³æ€§ NSCLC æ‚£è€…ï¼Œä¸”æœªæ¥å— TKIï¼Œä¸œéƒ¨åˆä½œè‚¿ç˜¤ç»„è¡¨ç°çŠ¶æ€ä¸è¶…è¿‡ 2ï¼Œä¸”æ—¢å¾€æ¥å—è¿‡ 1 æ¬¡æˆ–æ— é“‚ç±»åŒ–ç–—ã€‚å‚ä¸è€…äº 2019 å¹´ 6 æœˆè‡³ 2023 å¹´ 4 æœˆæ‹›å‹Ÿï¼Œå¹¶æŒç»­è·Ÿè¸ªè‡³ 2024 å¹´ 8 æœˆã€‚æ•°æ®åˆ†æäº 2025 å¹´ 4 æœˆ 5 æ—¥è‡³ 8 æœˆ 30 æ—¥è¿›è¡Œã€‚å¹²é¢„æªæ–½ï¼šæ´›æ‹‰æ›¿å°¼æ¯æ—¥<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1993805884852121600/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>é’å°‘å¹´å’Œå¹´è½»æˆäººç™Œç—‡çš„è½¬ç§»å¤å‘æ˜¯æ—©æœŸæ­»äº¡çš„å…³é”®é©±åŠ¨å› ç´ ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext:<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1993805894587101184/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (3æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨3æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>scKGBERTâ€”â€”ä¸€ç§ç”¨äºå•ç»†èƒè½¬å½•ç»„å­¦çš„çŸ¥è¯†å¢å¼ºå‹åŸºç¡€æ¨¡å‹</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsingle-cellã€transcriptomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šscKGBERT combines large scale RNA sequencing data with protein interaction networks to improve biomarker discovery and cell characterization for precision medicine...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/sckgbert-a-knowledge-enhanced-foundation-model-for-single-cell-transcriptomics/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>RNAæµ‹åºæ­ç¤ºè„‘è›‹ç™½OTULINå¦‚ä½•æ§åˆ¶tauè›‹ç™½è¡¨è¾¾ï¼Œå¹¶å¯èƒ½å½»åº•æ”¹å˜é˜¿å°”èŒ¨æµ·é»˜ç—…çš„æ²»ç–—ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šAlzheimerã€RNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šResearchers reveal OTULIN as a key regulator of tau production and RNA sequencing signatures in neurons, uncovering new therapeutic opportunities for Alzheimerâ€™s disease and related tauopathies...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/rna-seq-reveals-how-brain-protein-otulin-controls-tau-expression-and-could-transform-alzheimers-treatment/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>Lexogen å’Œ Ochre Bio æ¨è¿›å¤§è§„æ¨¡ RNA æµ‹åºæŠ€æœ¯ï¼Œä»¥åŠ é€ŸåŠŸèƒ½åŸºå› ç»„å­¦å’Œ RNA ç–—æ³•çš„å‘ç°ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsequencingã€genomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šLexogen and Ochre Bio generated large-scale functional genomics data from human hepatocytes, delivering high-fidelity RNA sequencing to advance AI-driven target...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/lexogen-and-ochre-bio-advance-large-scale-rna-sequencing-to-accelerate-functional-genomics-and-rna-therapy-discovery/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>å…ç–«</td>
<td>8</td>
</tr>
<tr>
<td>RNA-seq</td>
<td>8</td>
</tr>
<tr>
<td>å•ç»†èƒ</td>
<td>7</td>
</tr>
<tr>
<td>ç”Ÿä¿¡</td>
<td>7</td>
</tr>
<tr>
<td>ä»£è°¢</td>
<td>6</td>
</tr>
<tr>
<td>è¡°è€</td>
<td>5</td>
</tr>
<tr>
<td>methylation</td>
<td>5</td>
</tr>
<tr>
<td>è‚¿ç˜¤</td>
<td>4</td>
</tr>
<tr>
<td>sequencing</td>
<td>4</td>
</tr>
<tr>
<td>ChIP-seq</td>
<td>4</td>
</tr>
<tr>
<td>carcinoma</td>
<td>4</td>
</tr>
<tr>
<td>ç™Œç—‡</td>
<td>4</td>
</tr>
<tr>
<td>åŸºå› ç»„</td>
<td>3</td>
</tr>
<tr>
<td>Tç»†èƒ</td>
<td>3</td>
</tr>
<tr>
<td>æµ‹åº</td>
<td>3</td>
</tr>
<tr>
<td>single-cell</td>
<td>3</td>
</tr>
<tr>
<td>RNAseq</td>
<td>3</td>
</tr>
<tr>
<td>regex:onco(logy</td>
<td>logist</td>
</tr>
<tr>
<td>metabolic</td>
<td>3</td>
</tr>
<tr>
<td>ç©ºé—´ç»„å­¦</td>
<td>3</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-å…¬ä¼—å·"></a>ğŸ“° å…¬ä¼—å· å…¶ä»–å†…å®¹ (24æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg5MDk3Mzg4OA==&amp;mid=2247498520&amp;idx=1&amp;sn=ce00eb56f366724de36f356f6a2d452a" target="_blank" rel="noopener noreferrer">åŸºå› ç»„æ¯”è¾ƒåˆ†æä¸å†å¤æ‚ï¼gggenomesåŒ…ï¼ŒåŠ©ä½ å¿«é€Ÿç»˜åˆ¶å¤šå±‚æ¬¡åŸºå› ç»„å›¾è°±ï¼Œç§’å˜ç”Ÿä¿¡å¯è§†åŒ–é«˜æ‰‹ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247504084&amp;idx=2&amp;sn=939c7efbce1bd99f0aa5cd35a6c0a408" target="_blank" rel="noopener noreferrer">æœ€æ–°11+ç”Ÿä¿¡ï¼Œèšç„¦åŸºè´¨ç»†èƒ-å…ç–«ç»†èƒçš„äº’ä½œç½‘ç»œã€‚æœ¬æ–‡å®éªŒå®Œç¾è¯å®ç”Ÿä¿¡ç»“æœï¼Œå¹²æ¹¿ç»“åˆæ°åˆ°å¥½å¤„ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248844&amp;idx=2&amp;sn=52d22601f2446c0406e8dc039292e179" target="_blank" rel="noopener noreferrer">çº¯ç”Ÿä¿¡åˆ†æçš„å¤©èŠ±æ¿ï¼å“ˆåŒ»å¤§åˆ©ç”¨å¤šç»„å­¦+æ³›ç™Œåˆ†æï¼Œè¿˜èƒ½èåˆå•ç»†èƒï¼Œæ‹¿ä¸‹6åˆ†SCIå®è‡³åå½’ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg2NDcxMzYwNg==&amp;mid=2247490958&amp;idx=1&amp;sn=d3fea3f2e23850554681673d204dcd4c" target="_blank" rel="noopener noreferrer">IF=44: 7ç§ç©ºé—´ç»„å­¦å¹³å°,10ç§ç™Œç—‡ç±»å‹,é€¾1400ä¸‡ä¸ªç»†èƒè¿›è¡Œè·¨å¹³å°æ•´åˆåˆ†æ</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MjM5MzQ4NTk4MA==&amp;mid=2656511039&amp;idx=3&amp;sn=c41e487b3586513dd949a3f003d4fb1a" target="_blank" rel="noopener noreferrer">æ–°å…ç–«è°ƒèŠ‚åŠŸèƒ½ï¼è‹å·å¤§å­¦é™„å±ç¬¬å››åŒ»é™¢ç­‰å•ä½å‘æ–‡ï¼šæœ‰å‰æ™¯çš„æŠ—è‚¿ç˜¤æ²»ç–—é¶ç‚¹</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MjM5MzQ4NTk4MA==&amp;mid=2656511039&amp;idx=2&amp;sn=c88b2c36a9bbb238cf902129ac3e417d" target="_blank" rel="noopener noreferrer">å››å·å¤§å­¦èµµæ˜Ÿ/éƒ­å†°/è‚–é›„/å¼ èŠè‹±å›¢é˜Ÿåˆ†æ36ä¸‡äºº2911ç§è¡€æµ†è›‹ç™½ï¼Œæ­ç¤ºäº”ç§ä¸åŒå…±æš´éœ²æ¨¡å¼å½±å“å¿ƒè¡€ç®¡ä»£è°¢ç–¾ç—…çš„æœºåˆ¶</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkyNzcxMjEyMg==&amp;mid=2247498042&amp;idx=1&amp;sn=94a95c2fd7d51496a93f9537a4edec0e" target="_blank" rel="noopener noreferrer">å¥½æ€è·¯è¿™å°±æ°´çµçµåœ°å‡ºæ¥äº†ï¼æ¸©åŒ»å¤§å…ç–«ç»†èƒç‰¹å¼‚åˆ†æï¼Œå°æˆæœ¬å‘é«˜åˆ†ä¹Ÿä¸éš¾å®ç°ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247504084&amp;idx=5&amp;sn=9f716a6b459251975a7c4555a36ab028" target="_blank" rel="noopener noreferrer">æ°¨åŸºé…¸ä»£è°¢æ˜¯çœŸçš„ç«ï¼Œå¹²æ¹¿ç»“åˆè½»æ¾å‘7.5åˆ†2åŒºæ–‡ç« ã€‚ç°åœ¨ä¸‹æ‰‹è¿˜ä¸æ™šï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzk3NTY2NDk1Nw==&amp;mid=2247488334&amp;idx=1&amp;sn=bc2e80a109e4d73f52a431b7c5b66ee2" target="_blank" rel="noopener noreferrer">é»„èŠ©è‹·-ç™½è—œèŠ¦é†‡è‡ªç»„è£…çº³ç±³è¯å¤šé€šè·¯é€†è½¬RSVè‚ºç‚</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&amp;mid=2247507704&amp;idx=3&amp;sn=317c846a477676b4901eac0042aea879" target="_blank" rel="noopener noreferrer">Nat Methods | é¦–æ¬¡ç³»ç»Ÿç»˜åˆ¶éäººçµé•¿ç±»å…¨èº«å¤šç»„å­¦è¡°è€å›¾è°±ï¼å­”åº†é¹/æ½˜å…´åå›¢é˜Ÿæ­ç§˜ä¸ºä»€ä¹ˆæœ‰çš„å™¨å®˜è€çš„æ›´å¿«ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&amp;mid=2247507704&amp;idx=2&amp;sn=87fb8deb855197524362054546c3374d" target="_blank" rel="noopener noreferrer">æœ‰æœ›å¼€å¯ç™Œç—‡æ²»ç–—æ–°çºªå…ƒï¼šæ—åœ£å½©é™¢å£«è¯å®ï¼Œæ¨¡æ‹Ÿé¥¥é¥¿çš„â€œè¾Ÿè°·ç²¾â€å¯è®©è‚ç™Œç»ˆèº«å¯æ§</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg2NTE1MzU4NQ==&amp;mid=2247523475&amp;idx=1&amp;sn=baa23bf3c153204cfc9bc4519b32d097" target="_blank" rel="noopener noreferrer">å•ç»†èƒæ³¨é‡Šå¤ªéš¾ï¼Ÿè¿™ç¯‡å…¨ç½‘æœ€å…¨æŒ‡å—è®©ä½ ä»æ­¤ä¸è¿·èŒ«ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU1OTkyMTE4Mg==&amp;mid=2247489031&amp;idx=1&amp;sn=cf4923625552de6e944e87e0a70153c8" target="_blank" rel="noopener noreferrer">èšç„¦è¡°è€ï¼Œä¸­ç§‘é™¢åˆ˜å…‰æ…§å›¢é˜Ÿè¿è·çªç ´ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248844&amp;idx=7&amp;sn=ba714b997f457c5dc3d638f2212b730f" target="_blank" rel="noopener noreferrer">67åˆ†å·¨ä½œï¼Œå¸¦ä½ ç”¨çˆ†ç«çš„ä»£è°¢é‡ç¼–ç¨‹å®ç°å¼¯é“è¶…è½¦</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248844&amp;idx=6&amp;sn=89a51ffddf39ed00d731ab7f95f0f36b" target="_blank" rel="noopener noreferrer">Cell Genomæœ€æ–°åŠ›ä½œï¼å¤šç»„å­¦+å­Ÿå¾·å°”éšæœºåŒ–åˆ†æï¼Œç ´è§£è¡€æ¸…ä»£è°¢ç‰©ä¸æ…¢æ€§ç–¾ç—…çš„é—ä¼ å…³è”ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248844&amp;idx=5&amp;sn=78c33301480a9a5e9b80773ab0d2d6ac" target="_blank" rel="noopener noreferrer">28 æ ·æœ¬ IF40.4ï¼è§£å¯†ç‹çº¢é˜³é™¢å£«å›¢é˜Ÿçš„å•ç»†èƒåˆ›æ–°å¯†ç </a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248844&amp;idx=4&amp;sn=b264c0f510f445051315f581a22302a1" target="_blank" rel="noopener noreferrer">æœ€æ–°27+ç”Ÿä¿¡ï¼ŒåŸæ¥åªåšäº†è¿™äº›æ“ä½œï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248844&amp;idx=1&amp;sn=49a96c5f4a029221e606803f62dea4ed" target="_blank" rel="noopener noreferrer">è‚ç—…å­¦é¡¶åˆŠã€Journal of Hepatologyã€‘é‡ç£…æ¨å‡ºï¼šèƒ†æ±é…¸è°ƒæ§Tregç»†èƒ-èƒ†ç®¡ç–¾ç—…æ²»ç–—æ–°é¶ç‚¹</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzUxMzk5MjY5NA==&amp;mid=2247650785&amp;idx=3&amp;sn=e2c3b1e7e68e088d96425c71dd52674b" target="_blank" rel="noopener noreferrer">èƒ¡æˆ˜åˆ©/è‘£å­Ÿæ°å›¢é˜Ÿï¼šé¦–æ¬¡ç³»ç»Ÿæç»˜è¡€ç³–å¼‚å¸¸è¿›å±•è¿‡ç¨‹ä¸­çš„å¤šå™¨å®˜ä»£è°¢ç½‘ç»œåŠ¨æ€é‡å¡‘å›¾è°±</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzUxMzk5MjY5NA==&amp;mid=2247650785&amp;idx=2&amp;sn=e6c1118bcc83e4198cfd7b77a51649d4" target="_blank" rel="noopener noreferrer">Neuronï¼šæµ™æ±Ÿä¸­åŒ»è¯å¤§å­¦é™ˆå¿ /éƒ‘è‰³æ¦•å›¢é˜Ÿç ´è§£ã€Œè„‚è‚ªè¯±æƒ‘ã€çš„ä¸“å±ç¥ç»å¯†ç </a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkwMzY2NjkwNg==&amp;mid=2247495740&amp;idx=1&amp;sn=a9cc6dc7d8b3c06bbb0c47bf5a309a8e" target="_blank" rel="noopener noreferrer">è¿™ä¸ªç”Ÿä¿¡æ€è·¯å¯ä»¥å­¦ï¼Œç§‘å­¦é—®é¢˜éƒ½ç»†åŒ–äº†ã€‚è¿˜èƒ½é ç»„å­¦å‘ï¼Œä¸éœ€è¦åšæœºåˆ¶ã€‚</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkzMzY5NDk3NA==&amp;mid=2247493488&amp;idx=1&amp;sn=a4a3a68fbe8a25bd6352a73f5ffbf027" target="_blank" rel="noopener noreferrer">ä¸ºä»€ä¹ˆåªæœ‰25%çš„æ‚£è€…æœ‰æ•ˆï¼Ÿæ·±æŒ–110ä¾‹ä¸´åºŠæ•°æ®ï¼Œç»ˆäºæ‰¾åˆ°äº†å†³å®šèƒƒç™Œå…ç–«æ²»ç–—æˆè´¥çš„â€œç©ºé—´é’¥åŒ™â€ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzAwMzY4MTYxNw==&amp;mid=2655821453&amp;idx=2&amp;sn=466d137351db4ca36e6e3d7104b19f08" target="_blank" rel="noopener noreferrer">å·¨å™¬ç»†èƒçš„å¸¸è§14ç§åŠŸèƒ½è¡¨å‹ï¼Œæ£€æµ‹æ–¹æ³•å’Œç ”ç©¶æ€è·¯ç›˜ç‚¹ï¼Œä½ éƒ½çŸ¥é“å—ï¼Ÿ</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&amp;mid=2247790877&amp;idx=1&amp;sn=79bceebdb9f0d7a61f004b6a13537e05" target="_blank" rel="noopener noreferrer">Cellé‡ç£…ï¼šåäººå­¦è€…è¯å®ï¼Œå‹åŠ›ä¸ä»…è®©ä½ æ‰å¤´å‘ï¼Œè¿˜ä¼šå¼•å‘è‡ªèº«å…ç–«ï¼ŒåŸ‹ä¸‹é•¿æœŸè„±å‘éšæ‚£</a></li>
</ul>
</div>
</details>

<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (34æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308805" target="_blank" rel="noopener noreferrer">GSE308805 CDCA7 ä¿ƒè¿› MET1 ä»‹å¯¼çš„ç€ä¸ç²’å‘¨å›´å’Œç€ä¸ç²’æŸ“è‰²è´¨çš„ CG ç”²åŸºåŒ–ç»´æŒ [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303706" target="_blank" rel="noopener noreferrer">GSE303706 é»å·´å«©æºƒç–¡æ€§ç»“è‚ ç‚æ‚£è€…å’Œå¥åº·å¯¹ç…§ç»„çš„è‚ é“èŒç¾¤åˆ†æï¼šä¸€é¡¹åˆæ­¥ç ”ç©¶</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290148" target="_blank" rel="noopener noreferrer">GSE290148 DNAç”²åŸºåŒ–ç¼ºå¤±çš„ç§€ä¸½éšæ†çº¿è™«ä¸­MBD-2çš„åŸºå› ç»„å®šä½å’ŒåŠŸèƒ½[RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290147" target="_blank" rel="noopener noreferrer">GSE290147 DNAç”²åŸºåŒ–ç¼ºå¤±çš„ç§€ä¸½éšæ†çº¿è™«ä¸­MBD-2çš„åŸºå› ç»„å®šä½å’ŒåŠŸèƒ½[ChIP-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311623" target="_blank" rel="noopener noreferrer">GSE311623 RNAseq åˆ†æäº†è½¬æŸ“é¶å‘ INPPL1 çš„ siRNA (siSHIP2) å’Œéé¶å‘ siRNA (siCT) çš„ eSCC äººç±»ç»†èƒç³» (KYSE-410 å’Œ KYSE-30) çš„æƒ…å†µã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311620" target="_blank" rel="noopener noreferrer">GSE311620 RNAæµ‹åºåˆ†æäº†ç»SHIP2è¯ç†æŠ‘åˆ¶å‰‚å¤„ç†çš„eSCCäººç»†èƒç³»ï¼ˆKYSE-410ï¼‰çš„RNAè¡¨è¾¾è°±ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308255" target="_blank" rel="noopener noreferrer">GSE308255 çŸ®ç‰µç‰›èŠ±ç“£èº«ä»½è°ƒèŠ‚å› å­ PhDEF çš„ç»†èƒå±‚ç‰¹å¼‚æ€§åŠŸèƒ½ [ChIP-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE283857" target="_blank" rel="noopener noreferrer">GSE283857 é€šè¿‡åŸºäºç‰‡æ®µçš„å‘ç°ç›´æ¥é¶å‘ç™ŒåŸºå› å°çœ¼ç•¸å½¢ç›¸å…³è½¬å½•å› å­ (MITF)</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE283856" target="_blank" rel="noopener noreferrer">GSE283856 é€šè¿‡åŸºäºç‰‡æ®µçš„å‘ç°ç›´æ¥é¶å‘ç™ŒåŸºå› å°çœ¼ç•¸å½¢ç›¸å…³è½¬å½•å› å­ (MITF) [Cut &amp; Tag]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE280562" target="_blank" rel="noopener noreferrer">GSE280562 IDH2 çªå˜å¼•èµ·çš„åŸºå› å†…è¡¨è§‚é—ä¼ å¤±è°ƒä¸ SRSF2 çªå˜ååŒä½œç”¨ï¼Œå¯¼è‡´å…³é”®è½¬å½•è°ƒæ§å› å­çš„é”™è¯¯å‰ªæ¥ [BiSulfite-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE240460" target="_blank" rel="noopener noreferrer">GSE240460 åˆ†å­å¯å¡‘æ€§å¯¼è‡´å¹¼å¹´å‹éª¨é«“å•æ ¸ç»†èƒç™½è¡€ç—…ä¸­çš„ç™Œèƒšé‡ç¼–ç¨‹å’Œæ²»ç–—è„†å¼±æ€§</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE235533" target="_blank" rel="noopener noreferrer">GSE235533 åŒç§å¼‚ä½“ååº”æ€§å’Œè‡ªèº«ååº”æ€§æ±‡èšï¼Œæ”¯æŒBç»†èƒè¡¨ä½é¶å‘</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311675" target="_blank" rel="noopener noreferrer">GSE311675 SHIP2-PLK1 ä¸²æ‰°ä¿ƒè¿›é£Ÿç®¡é³çŠ¶ç»†èƒç™Œå¯¹åŒé‡æŠ‘åˆ¶çš„æ•æ„Ÿæ€§</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311621" target="_blank" rel="noopener noreferrer">åˆ©ç”¨ CRISPR/Cas9 æŠ€æœ¯æ•²é™¤ SHIP2 åŸºå› çš„ eSCC äººç»†èƒç³» (KYSE-410) çš„ RNA æµ‹åºåˆ†æ GSE311621</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307191" target="_blank" rel="noopener noreferrer">GSE307191 ç¢±åŸºå¯¹åˆ†è¾¨ç‡æŸ“è‰²ä½“æ„è±¡æ•è·æ­ç¤ºæŸ“è‰²è´¨ç»“æ„æœ¬è´¨çš„æœºåˆ¶æ€§è§è§£ [ChIP-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298629" target="_blank" rel="noopener noreferrer">GSE298629 Lrig1é™æ­¢å¹²ç»†èƒç¾¤çš„å•ç»†èƒè½¬å½•ç»„åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289504" target="_blank" rel="noopener noreferrer">GSE289504 è‡´ç—…å²›è½¬å½•è¯±å¯¼åŸŸç›¸å…³çš„ç»†èŒæŸ“è‰²è´¨é‡å¡‘ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285035" target="_blank" rel="noopener noreferrer">GSE285035 ä»£è°¢è°ƒæ§ä½¿é…µæ¯èƒ½å¤Ÿç«‹å³é€‚åº”èƒ½é‡èƒè¿«</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281414" target="_blank" rel="noopener noreferrer">GSE281414 ç¢±åŸºå¯¹åˆ†è¾¨ç‡æŸ“è‰²ä½“æ„è±¡æ•è·æ­ç¤ºæŸ“è‰²è´¨ç»“æ„æœ¬è´¨çš„æœºåˆ¶è§è§£ [ATAC-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE275344" target="_blank" rel="noopener noreferrer">GSE275344 æŒç»­å­˜åœ¨çš„ STAT3 ç›¸å…³æŸ“è‰²è´¨æ„è±¡å†…çš„åè°ƒåŸºå› è¡¨è¾¾ä¿ƒè¿›è‚ç»†èƒç™Œè¿›å±• [HiChIP]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE271136" target="_blank" rel="noopener noreferrer">GSE271136 åŒ–ç–—è€è¯ç»†èƒç¾¤çš„åˆ†å­ç‰¹å¾å¯æ”¹å–„å„¿ç«¥æ€¥æ€§é«“ç³»ç™½è¡€ç—… (AML) çš„é£é™©åˆ†å±‚å’Œæ²»ç–—ååº”é¢„æµ‹ [pAML PDX scRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE271134" target="_blank" rel="noopener noreferrer">GSE271134 åŒ–ç–—è€è¯ç»†èƒç¾¤çš„åˆ†å­ç‰¹å¾å¯æ”¹å–„å„¿ç«¥æ€¥æ€§é«“ç³»ç™½è¡€ç—… (AML) çš„é£é™©åˆ†å±‚å’Œæ²»ç–—ååº”é¢„æµ‹ [pAML PDX Bulk RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE270894" target="_blank" rel="noopener noreferrer">GSE270894 åŒ–ç–—è€è¯ç»†èƒç¾¤çš„åˆ†å­ç‰¹å¾å¯æ”¹å–„å„¿ç«¥æ€¥æ€§é«“ç³»ç™½è¡€ç—… (pAML) çš„é£é™©åˆ†å±‚å’Œæ²»ç–—ååº”é¢„æµ‹ [pAML æ‚£è€… scRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE270892" target="_blank" rel="noopener noreferrer">GSE270892 åŒ–ç–—è€è¯ç»†èƒç¾¤çš„åˆ†å­ç‰¹å¾å¯æ”¹å–„å„¿ç«¥æ€¥æ€§é«“ç³»ç™½è¡€ç—… (pAML) çš„é£é™©åˆ†å±‚å’Œæ²»ç–—ååº”é¢„æµ‹ [pAML æ‚£è€…æ‰¹é‡ RNA æµ‹åº]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE236265" target="_blank" rel="noopener noreferrer">GSE236265 YAPé¶å‘TEAD4-NF-ÎºBå¤åˆç‰©å¹¶æŠ‘åˆ¶ccRCCè‚¿ç˜¤ç”Ÿé•¿</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE79936" target="_blank" rel="noopener noreferrer">GSE79936 ç§€ä¸½éšæ†çº¿è™«çš„ X æŸ“è‰²ä½“äº¤å‰å½¢æˆå’ŒåŸºå› ç»„ç¨³å®šæ€§å— xnd-1 ç‹¬ç«‹è°ƒæ§</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311188" target="_blank" rel="noopener noreferrer">GSE311188 å…ˆå‰é«˜çº¤ç»´æ‘„å…¥å¯¹è‚ ç³»è†œè„‚è‚ªå’Œè‚ é“ç»„ç»‡å¯¹éšåé«˜è„‚è‚ªå–‚å…»çš„ç»†èƒååº”äº§ç”Ÿå½±å“ [16s rRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311074" target="_blank" rel="noopener noreferrer">GSE311074 COPG1 æ˜¯ç™Œç—‡è¿›å±•å’ŒåŒ–ç–—è€è¯æ€§çš„é€‰æ‹©æ€§å¿…éœ€è°ƒæ§å› å­ï¼šä¸€é¡¹å…¨é¢çš„æ³›ç™Œç ”ç©¶</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310739" target="_blank" rel="noopener noreferrer">GSE310739 é²¸ç±»å•æ ¸ RNA æµ‹åºå°†å¿ƒè„ä¿æŠ¤åŸºå›  FHL2 å®šä½ä¸ºæ¨è¿›çŒªåˆ°äººå¿ƒè„å¼‚ç§ç§»æ¤çš„é¶ç‚¹</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308807" target="_blank" rel="noopener noreferrer">GSE308807 CDCA7 ä¿ƒè¿› MET1 ä»‹å¯¼çš„ç€ä¸ç²’å‘¨å›´å’Œç€ä¸ç²’æŸ“è‰²è´¨çš„ CG ç”²åŸºåŒ–ç»´æŒ [BiSulfite-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293406" target="_blank" rel="noopener noreferrer">GSE293406 YKT6 é€šè¿‡ USP7 ä»‹å¯¼çš„å»æ³›ç´ åŒ–ä½œç”¨ç¨³å®š Î²-cateninï¼Œä»è€Œä¿ƒè¿›è†€èƒ±ç™Œè¿›å±•</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE283329" target="_blank" rel="noopener noreferrer">GSE283329 ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…å”¾æ¶²å¾®ç”Ÿç‰©ç¾¤å¤±è°ƒå’Œä»£è°¢ç´Šä¹±</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282991" target="_blank" rel="noopener noreferrer">GSE282991 æ­»åé—´éš”ä¼°è®¡çš„microRNAè½¬å½•ç»„åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282620" target="_blank" rel="noopener noreferrer">GSE282620 DGP1å®¶æ—æˆå‘˜é€šè¿‡æ•´åˆä¸¤ç§ç¯å¢ƒä¿¡å·ä»‹å¯¼æ°´ç¨»çš„å¤§è§„æ¨¡ä»£è°¢é‡å¡‘</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2025-11-27 21:33</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>